IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial

Core Insights - IDEAYA Biosciences is set to participate in investor relations events and has provided updated guidance on the topline data release from the Phase 2/3 OptimUM-02 trial for HLA-A2*-negative metastatic uveal melanoma [1][5] Upcoming Events - The company will host a webcast during the Bank of America Merrill Lynch Health Care Conference on May 12, 2026, featuring a fireside chat with CEO Yujiro S. Hata [2] - Another fireside chat will take place at the Stifel 2026 Targeted Oncology Virtual Forum on May 19, 2026, also featuring CEO Yujiro S. Hata [2] Company Overview - IDEAYA is focused on precision medicine in oncology, aiming to discover and develop targeted therapies for cancer [3] - The company integrates small-molecule drug discovery, structural biology, and bioinformatics to create tailored therapies aligned with genetic disease drivers [3] - IDEAYA has a pipeline that includes synthetic lethality and antibody-drug conjugates (ADCs) for solid tumor indications [3] Updated Guidance - The database lock for the OptimUM-02 trial is expected in the first half of April, with topline data analysis to follow [5]